Accredited E-Newsletter Series

The Advent of Four-drug Combinations in the Frontline Setting: How Will This Change Current Practice?
The Advent of Four-drug Combinations in the Frontline Setting: How Will This Change Current Practice?
CME, CPE
Shaji K. Kumar, MD
Release Date: April 01, 2021
Expiration Date: April 01, 2022

There has been an increasing interest in the potential for moving beyond three-drug combinations to improve the treatment of patients with multiple myeloma in the frontline setting. In this activity, Dr. Kumar discusses the rationale, decision making, and trials that explore four-drug combinations for patients with newly diagnosed multiple myeloma. He also explains the efficacy and toxicity burden of these regimens.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
CE ExpiredView Only, No Credit
 
Planning Treatment Strategies for Older Adults with Myeloma: Considerations for Assessment of the Elderly/Frail Patient
Planning Treatment Strategies for Older Adults with Myeloma: Considerations for Assessment of the Elderly/Frail Patient
CME, CPE
Sascha Alexander Tuchman, MD, MHS
Release Date: February 25, 2021
Expiration Date: February 25, 2022

It is important to assess age and fitness when formulating management approaches for a patient with multiple myeloma. In this newsletter, Dr. Tuchman explains the optimal method for assessing the impact of aging and the appropriate considerations for evaluating older patients. He also discusses the different geriatric assessments and instruments best suited to assess elderly patients with multiple myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
CE ExpiredView Only, No Credit